OR WAIT 15 SECS
What are your strategic priorities for CSIR in 2025, particularly in the realms of life sciences research? Are...
In a move set to redefine non-invasive disease detection, Bengaluru-based Remidio, a global leader in artifici...
Bengaluru-based startup Stance Health, an innovator in musculoskeletal (MSK) care, has secured $1 million...
Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific Krios ...
RIPPLE EFFECT of Cancer Drug Duty Cuts
To ease the financial strain on patients, the Union Budget 2025-26 has removed Basic Customs Duty (BCD) on 36 life-saving drugs used for cancer, rare diseases, and chronic conditions. This move is expected to make essential treatments more affordable by lowering overall costs. However, the real question remains: will this truly reduce the financial burden on patients? As prices decrease, what effects will this have on pharmaceutical companies, particularly in terms of sales and competition? Most importantly, how will local players adapt to these changes?
For Feedback, please email us at: communications@mmactiv.com
Sign up here to access BioSpectrum India Flip Book.
Sign up here to access BioSpectrum India Flip Book
